Last reviewed · How we verify
NCT07124624: IDEAL2
Stepped-Wedge Cluster Randomized Trial of AI-Assisted CTA Detection for Intracranial Aneurysms in Regional Hospitals
NA trial testing AI-Assisted CTA Interpretation in Intracranial Aneurysm in 14,400 participants. Not yet recruiting.
31 August 2026
Quick facts
| Lead sponsor | Jinling Hospital, China |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 14,400 |
| Start date | 9 October 2025 |
| Primary completion | 31 August 2026 |
| Estimated completion | 31 August 2029 |
Drugs / interventions tested
- AI-Assisted CTA Interpretation
- Standard CTA Interpretation
Conditions studied
- Intracranial Aneurysm — all drugs for Intracranial Aneurysm →
- CT Angiography — all drugs for CT Angiography →
- AI (Artificial Intelligence) — all drugs for AI (Artificial Intelligence) →
- Cluster Randomized Trial — all drugs for Cluster Randomized Trial →
Sponsor
Jinling Hospital, China
Who can join
18 and older, any sex, with Intracranial Aneurysm or CT Angiography. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study (IDEAL 2) is a nationwide stepped-wedge cluster-randomized trial designed to prospectively enroll over 14,400 patients undergoing outpatient head CT angiography (CTA). The trial will be conducted across more than 72 regional hospitals in China. Clusters were randomly assigned to nine randomization groups. In accordance with the stepped-wedge design, clusters will sequentially transition from the control condition (standard human diagnosis) to the intervention condition (AI-assisted diagnosis) at regular intervals over a 10-month period, until all clusters receive the intervention. The primary outcome is the detection rate of intracranial aneurysms. Secondary outcomes include patient prognosis and clinical outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07124624
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Intracranial Aneurysm
Currently open trials in the same condition.
- NCT07123818 — AI for Detection of Brain Aneurysm: Low-cost Opportunistic Screening · NA · active not recruiting
- NCT06494436 — Microvention AnEurysm & STroke Real-life Data cOllection · recruiting
- NCT06588543 — Patient-specific Planning of Minimally Invasive Brain Interventions Based on Vascular-hemodynamic Mapping · recruiting
- NCT05831202 — SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial · Phase 3 · active not recruiting
- NCT06416657 — General Anesthesia vs Local Anesthesia for Endovascular Treatment in Patients With Unruptured Intracranial Aneurysm Usin · NA · recruiting
Other Jinling Hospital, China trials
Trials by the same sponsor.
- NCT07297238 — Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration. · NA · recruiting
- NCT07237542 — Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction · NA · recruiting
- NCT07230314 — Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inh · Phase 2 · not yet recruiting
- NCT06177522 — Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07294859 — Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07124624 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jinling Hospital, China
- Last refreshed: 20 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07124624.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing